XY Capital Ltd Buys 56,306 Shares of Immutep Limited (NASDAQ:IMMP)

XY Capital Ltd grew its stake in shares of Immutep Limited (NASDAQ:IMMP) by 52.0% during the fourth quarter, Holdings Channel reports. The institutional investor owned 164,655 shares of the biotechnology company’s stock after purchasing an additional 56,306 shares during the quarter. Immutep comprises 0.2% of XY Capital Ltd’s portfolio, making the stock its 26th biggest holding. XY Capital Ltd’s holdings in Immutep were worth $357,000 at the end of the most recent reporting period.

Separately, Meridian Wealth Management LLC boosted its holdings in Immutep by 4.5% in the third quarter. Meridian Wealth Management LLC now owns 398,450 shares of the biotechnology company’s stock valued at $881,000 after acquiring an additional 17,250 shares in the last quarter. 2.32% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Robert W. Baird boosted their price target on Immutep from $6.00 to $7.00 and gave the stock an “outperform” rating in a research report on Friday, November 15th.

Immutep Trading Down 0.5 %

NASDAQ IMMP opened at $2.02 on Monday. The company has a quick ratio of 18.25, a current ratio of 18.25 and a debt-to-equity ratio of 0.01. The stock’s 50-day moving average price is $2.04 and its 200-day moving average price is $2.10. Immutep Limited has a 52 week low of $1.66 and a 52 week high of $3.34.

Immutep Company Profile

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.